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The immune system is a complex system able to recognize a wide variety of host agents, through diﬀerent biological processes. For
example, controlled changes in the redox state are able to start diﬀerent pathways in immune cells and are involved in the killing of
microbes. The generation and release of ROS in the form of an “oxidative burst” represent the pivotal mechanism by which
phagocytic cells are able to destroy pathogens. On the other hand, impaired oxidative balance is also implicated in the
pathogenesis of inﬂammatory complications, which may aﬀect the function of many body systems. NADPH oxidase (NOX)
plays a pivotal role in the production of ROS, and the defect of its diﬀerent subunits leads to the development of chronic
granulomatous disease (CGD). The defect of the diﬀerent NOX subunits in CGD aﬀects diﬀerent organs. In this context, this
review will be focused on the description of the eﬀect of NOX2 deﬁciency in diﬀerent body systems. Moreover, we will also
focus our attention on the novel insight in the pathogenesis of immunodeﬁciency and inﬂammation-related manifestations and
on the protective role of NOX2 deﬁciency against the development of atherosclerosis.
1. Introduction
Nicotinamide adenine dinucleotide phosphate (NAPDH)
oxidase (NOX) is a multimeric complex composed of
enzymes of the NOX family [1]. NOX2 is a transmembrane
protein ﬁrstly identiﬁed in phagocytic cells (e.g., neutrophils,
eosinophils, and macrophages) [2] and dendritic cells [3–6].
It plays a crucial role in antimicrobial host defence and
inﬂammation. NOX2 deﬁciency leads to the development
of chronic granulomatous disease (CGD), a primary immu-
nodeﬁciency characterized by life-threatening bacterial and
fungal infections [7]. In addition to recurrent infections,
patients with CGD also suﬀer from impaired inﬂammatory
responses leading to the development of Crohn’s-like inﬂam-
matory bowel disease (IBD) [8, 9] and other inﬂammatory
complications [7, 10, 11]. Recently, increased reactive oxygen
species- (ROS-) independent inﬂammasome activation and
impaired autophagy, resulting in increased IL-1b release,
have been shown in NOX2-deﬁcient phagocytes [12, 13].
The treatment with the IL-1b receptor inhibitor (anakinra)
resulted in decreasing the activation of inﬂammasome and
in restoring autophagy in mice with CGD in vitro and
in vivo. While the treatment seems to exert the same eﬀect
in human cells in vitro, the treatment in vivo is associated
with contrasting results in humans [14, 15]. Rapamycin, a
potent mammalian target of rapamycin (mTOR) inhibitor
and autophagy inducer, has been shown to be able to restore
autophagy and to regulate inﬂammasome activation in
patients with CGD, unravelling new therapeutic opportuni-
ties for the treatment of inﬂammatory manifestations in
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CGD [16, 17]. Apart from its well-characterized role in the
phagocyte function, NOX2 seems to be also implicated in
the function of other diﬀerent organs. In fact, NOX2 is also
expressed in endothelial cells [18], cardiomyocytes [19],
hematopoietic stem cells (HSC) [20, 21], and platelets [22]
and its upregulation has been shown to be involved in neuro-
degenerative disease [23], neoplasms [24], and cardiovascular
diseases [25–28]. Recent studies suggest that NOX2 activa-
tion is also involved in the development of atherosclerosis.
In patients with CGD and in heterozygous carriers, the reduc-
tion of the ROS production is associated with increased levels
of ﬂow-mediated artery dilatation, thus implying a lower
risk of developing atherosclerotic manifestations [29–32].
Other diﬀerent NOX isoforms are implicated in diverse
physiological functions, and they can be identiﬁed in numer-
ous cell types [33]. Evidence suggest that NOX/DUOX
enzymes are implicated in a number of biological processes
including host defence, regulation of the vascular tone, hor-
mone synthesis, fertilization, cell proliferation and diﬀerenti-
ation, and formation of the extracellular matrix [33, 34].
In this review, we will summarize the eﬀect of NOX2 deﬁ-
ciency in diﬀerent body systems, focusing our attention on the
novel insight in the pathogenesis of immunodeﬁciency and
inﬂammation-related manifestations and on the protective
role of NOX2 deﬁciency against the development of athero-
sclerosis. We will also focus on the novel insight in the deﬁni-
tion of the clinical phenotype in heterozygous and female
carriers and on the eﬃcacy of novel and traditional potential
therapeutic approach. Moreover, we will summarize the role
of other NOX/DUOX enzymes in the function of diﬀerent
body systems and in the development of disease in humans.
2. NADPH Oxidase: Structure and Function
NOX plays a pivotal role in the production of ROS and, in
particular, of the superoxide anion (O2
−) at the expense of
NADPH. Seven genes have been identiﬁed encoding for
NOX isoforms:NOX1 toNOX5, including CYBB gene encod-
ing for NOX2, DUOX1, and DUOX2 [33, 35]. The diﬀerent
NOX isoforms in humans are involved in a wide range of
cellular processes, including apoptosis, host defence, cellular
signal transduction, oxygen sensing, and angiogenesis.
Although NOX is ubiquitously expressed, the distribution
of diﬀerent isoforms is cell or tissue speciﬁc, allowing each
NOX a distinct physiological and pathological function. All
the members of the NOX family have conserved structural
properties which are responsible for their catalytic activity.
In particular, each homolog is composed of six or seven trans-
membrane domains, with two hemes in theN-terminal region
containing histidine residues and a NADPH-binding site in
the cytoplasmic C-terminal. Moreover, all the isoforms form
multimeric complexes characterized by the presence of a core
catalytic subunit and up to ﬁve regulatory subunits [36]. The
regulatory subunits have essential biological roles. In particu-
lar, the regulatory subunits p22phox, DUOX activator 1
(DUOXA1), and DUOXA2 are involved in the maturation
and expression of the NOX/DUOX subunits in cell mem-
branes; p67phox and NOX activator 1 (NOXA1) are essential
for enzyme activation; p47phox, NOX organizer 1 (NOXO1)
and p40phox have a role in spatial organization of the com-
plex. Some NADPH oxidase isoforms, including NOX2, also
rely on a small GTPase (RAC1 or RAC2) for their activation
[37]. The NOX2 complex consists of six subunits, including
two membrane molecules (NOX2 and p22phox), three with
a cytosolic distribution (p47phox, p67phox, p40phox), and
the G-protein Rac [1] (Figure 1) [33]. The catalytic core of
the NOX2 complex is represented by a membrane heterodi-
mer, composed of NOX2 and p22phox (Figure 1), which
constitutes the ﬂavocytochrome b558 [38]. It is constitutively
expressed in the plasma membrane and in the membrane of
speciﬁc granule of the neutrophils [39]. In this context, the
NOX2 subunit plays a key role in the transfer of electrons
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Figure 1: Schematic representation of the inactive and active forms of the NADPH oxidase complex. The complex consists of six subunits.
NOX2 and p22phox are associated to form a heterodimer bound to the plasma membrane in both the inactive and the active forms. In resting
conditions, p47phox, p67phox, p40phox, and the G-protein Rac are located in the cytosol. In the active form, the cytosolic subunits associate
with the membrane-bound NOX2/p22phox heterodimer. The active NADPH oxidase generates superoxide (O2
−) by transferring electrons
from NADPH inside the cell across the membrane and coupling them to molecular oxygen.
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from NADPH via FAD and heme to molecular oxygen
within the phagosome [40] (Figure 1). NOX2 in humans
is encoded by the CYBB gene and is composed of two
domains, the N-terminal bis-heme cytochrome b, struc-
tured in a six a-helical transmembrane segment complexe,
and the C-terminal FNR, which contains FAD- and
NADPH-binding sites [41–43]. In resting cells, the NADPH
oxidase cytosolic subunits, p47phox, p67phox, and
p40phox associate in a trimeric complex through speciﬁc
domains (Figure 1) [44–46]. In the active form of the
NOX2 complex, the trimeric complex migrates to the
plasma membrane where it interacts with NOX2 and
p22phox. p47phox plays a prominent role in the processes
of binding and translocation of the cytosolic subunits to
the membrane and the subsequent anchoring to p22phox
(Figure 1) [47]. In order to prevent ROS overproduction,
the protein kinase C- (PKC-) related phosphorylation path-
way is implicated in the modulation of these interactions
and in particular in the regulation of the interaction
between p47phox and p22phox. In particular, in the free
and complexed p47phox subunits, the interaction of the
autoinhibitory region (amino acids 292-340) with the two
SH3 domains prevents its binding to p22phox and, there-
fore, the NOX2 activation [48]. Upon stimulation, the
phosphorylation of the speciﬁc serine residues, Ser 303
and 304, activates p47phox, thus allowing the recruitment
of p67phox to the trimeric complex within the cytosol
(Figure 1) [46, 49]. In turn, p47phox leads to membrane
translocation through the binding to p22phox and contrib-
utes to the ﬁnal assembly of the NOX complex that also
includes the p22phox [50]. Rac2 and Rap1A, two proteins
of the guanine nucleotide-binding proteins family, are also
required for the full activation of the NOX complex [51].
Rac2 is located in the cytosol in a dimeric complex with
Rho-GDI (guanine nucleotide dissociation inhibitor), while
Rap1A is a membrane protein [51, 52]. During the activa-
tion, the Rac2-guanosine triphosphate (GTP) complex
translocates to the external membrane within the fully
assembled multimeric cytosolic complex [53, 54]. The role
of Rap1A in the activation of NADPH oxidase is controver-
sial (reviewed in [55]). In fact, Rap1a is expressed at high
levels in human neutrophils and copuriﬁes with the p22 sub-
unit of the NADPH oxidase [56–58]. Moreover, activating
and inhibitory Rap1 mutants can modify the activity of the
phagocyte NADPH oxidase [59, 60]. However, even though
cell-free NADPH activation seems to be impaired when
the cytosol of neutrophil is depleted of small GTPases and
recombinant Rap1A is able to restore NADPH oxidase acti-
vation, normal levels of Rap1A have been identiﬁed in neu-
trophil membranes from patients with CGD, suggesting
that the absence the cytochrome b558 does not aﬀect the
expression of this protein and its presence in the membrane
[61]. On the other hand, even though the initial rate of O2
−
in response to formylated peptide and phorbol ester was
reduced in Rap1a−/− mice, the sustained induction of
superoxide production was not signiﬁcantly reduced, sug-
gesting that unlike Rac2, Rap1A is not necessary for the
response of the neutrophil to formylated peptide or phorbol
ester [62].
The interaction with the regulatory proteins present in
the cytosol is able to induce a conformational change in
NOX2 which leads to its activation and to the electron ﬂow.
Studies in vitro suggest that the activation of the oxidase
may be obtained in the absence of p47phox but not in the
absence of p67phox or Rac [63–65]. Moreover, evidence sug-
gests that p67phox plays a pivotal role in the conformational
remodelling of NOX2 [66–68]. In particular, the region com-
prising the residues 199–210 [69] or 190–208 [70] of
p67phox has been identiﬁed as responsible of the activation
of the oxidase.
NOX2 complex plays a key role in killing the microor-
ganisms in phagocytic leukocytes. In particular, the interac-
tion of the external membrane of the phagocytic cell with
the bacteria leads to the internalization of a segment of the
plasma membrane. This interaction eventually leads to the
formation of the intracellular vesicle, where the oxidants
O2
− and O2-derived products promote K
+ inﬂux and induce
an increase of the pH within the phagosome [71]. The
increase in pH and the K+ inﬂux provides an optimal milieu
for the activation of the functions of the major granule prote-
ases, elastase, cathepsin G, and proteinase 3 [72]. In fact, the
alkaline pH together with the K+ inﬂux is able to promote the
dissociation of these enzymes from the anionic sulphated
proteoglycan matrix to which they are bound.
NOX1 was the ﬁrst homolog of NOX2 to be described
[73]. The NOX1 gene maps on the X-chromosome both in
humans and mice. NOX1 is highly expressed in the colon
epithelium [74]; however, it is also expressed in other cell
types, including vascular smooth muscle cells, endothelial
cells, and osteoclasts. NOX1 functions in a complex with
p22phox [74] and requires two additional proteins, NOXO1
and NOXA1, which are also present in the colon epithelium.
NOX1 is activated by the small GTPase Rac, which acts
through a direct binding to NOX1 or to the TPR domain
of the activator subunit NOXA1. Recent studies in mouse
models suggest that NOX1 is implicated in the control of cell
proliferation induced by diﬀerent bacteria, including Lacto-
bacilli [75]. NOX1 may also contribute to mucosal repair
after injury, as suggested by the evidence of impaired muco-
sal healing in an intestinal epithelial-speciﬁc Nox1 knockout
model [76].
The gene encoding for human NOX3 maps on chromo-
some 6.NOX3 is speciﬁcally expressed in the inner ear, where
it is required for the proper development of otoconia crystals
of the vestibular system. It can also be expressed at low levels
in the fetal spleen, fetal kidney, skull bone, and brain [77–80].
NOX3 depends on p22phox for its activation [81, 82].
Indeed, the production of ROS by NOX3 is inhibited by trun-
cated p22phox [81]. However, no vestibular dysfunction has
been reported for p22phox-deﬁcient CGD patients.
NOX4 was ﬁrst identiﬁed in kidney epithelial cells, but
subsequently, its expression has been detected also in several
other cell types, including vascular smooth muscle (VSMC),
endothelial cells, cardiomyocytes, skeletal muscle, osteo-
clasts, neurons, and microglia [33, 83]. Diﬀerently from other
NOX complexes, the activity of NOX4 does not require cyto-
solic regulatory subunits even though its activity seems to be
enhanced by association with p22phox [70]. Furthermore,
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NOX4 is the only member of the family which localizes
to mitochondria, contributing to mitochondrial ROS levels
[84, 85].
NOX5 is expressed in the spleen testis and endothelial
cells [86]. NOX5 oxidase is likely to function as a stand-
alone protein since no interactions with any of the known
regulatory subunits have been detected. NOX5 oxidase has
a unique amino terminal Ca2+-binding domain which allows
NOX5 oxidase activity to be regulated by increases in cyto-
solic Ca2+ concentration, which could be important in
chronic vascular diseases [87].
DUOX1 and DUOX2 were initially cloned from porcine
and human thyroid glands [88, 89]. However, their expres-
sion does not seem to be conﬁned to the thyroid gland. In
fact, they are also expressed in the respiratory and gastroin-
testinal tracts [90–93] where they are involved in the host
defence. DUOX1 and DUOX2 diﬀer from the other NOX
isoforms because of the homology of the N-terminal domain
with the peroxidases [94]. Moreover, NOX5 [95], DUOX1,
and DUOX2 [96] are calcium-dependent NADPH oxidase.
Finally, while similarly to NOX2, NOX1, NOX3, and NOX5
produce O2
−, which is subsequently converted into H2O2,
NOX4, DUOX1, and DUOX2 are able to directly produce
H2O2. The activity of DUOX is itself regulated by H2O2 levels
[97, 98]. The H2O2 produced by DUOX2 is able to support
the generation of hypothiocyanite, an antimicrobial com-
pound eﬀective against a broad range of bacteria [99–101].
In the thyroid gland, the H2O2 generated by DUOX2 is
necessary to allow the oxidation of the iodide by thyroid
peroxidase (TPO) [102]. DUOX2 mutations lead to thyroid
dyshormonogenesis, resulting in transient to severe congeni-
tal hypothyroidism.
3. NADPH Oxidase Deficiency:
Model of Inheritance
Mutations in one of the genes encoding the components of
the NADPH oxidase complex cause chronic granulomatous
disease (CGD), a rare inherited immunodeﬁciency syndrome
with an estimated frequency of 1/200,000 to 1/250,000
newborns. The disorder can be inherited in an X-linked or
autosomal recessive (AR) manner and comprises four main
genetic forms. The most common form of CGD is the X-
linked recessive CGD caused by mutations in the CYBB gene,
encoding the NOX2 protein. X-CGD represents about 60–
70% of the total cases reported to date [103]. The other forms
of CGD are AR and are due to mutations in CYBA, NCF1,
and NCF2, encoding p22phox, p47phox, and p67phox,
respectively [104]. p47phox deﬁciency is responsible for
approximately 30% of AR-CGD, while p22phox and
p67phox deﬁciencies account for the remaining 10% of cases
(about 5% each). To date, only one case of AR-CGD due to
mutation of the NCF4 gene, encoding p40phox, has been
reported [105]. Diﬀerent kinds of mutations have been so
far reported, including small indel, missense, nonsense, and
splice mutations. Missense mutations are frequent in XR-
CGD, reducing the NOX2 expression and functionality in
phagocytes at a diﬀerent extent. The X910 variant identiﬁes
the form with null protein and oxidase activity; X91− refers
to the form with residual protein expression and reduced,
but not absent activity, whereas the X91+ variant is charac-
terized by the normal expression of the protein, which, how-
ever, is not functional. Again, in the AR forms, the proteins
may be absent (A470, A220, and A670) or normally
expressed with residual activity of NADPH oxidase.
Dominant negative RAC2 mutation has been reported
in 2 male infants [106–108]. In the ﬁrst case, it was associ-
ated with soft tissue infections, neutrophilia, and neutrophil
chemiotaxis deﬁciency [106, 107]. The second case was
identiﬁed in the context of the newborn screening for severe
combined immunodeﬁciency because of a reduction of the
T cell receptor excision circles [108]. Apart from the neu-
trophil dysfunction, this patient also showed leukocytosis,
CD4 lymphopenia, and reduced levels of IgA and IgM
[108]. More recently, whole exome sequencing revealed a
homozygous nonsense loss of function mutation in two sib-
lings with common variable disease, born to consanguineous
parents [109]. The clinical phenotype was characterized by
recurrent sinopulmonary infections, bronchiectasis, failure
to thrive, poststreptococcal glomerulonephritis, coagulation
factor XI deﬁciency, urticaria, food allergy, erythematous pla-
ques, arthralgia, autoimmune thyroiditis, growth hormone
deﬁciency, and hyperparathyroidism. The immunological
phenotype included progressive hypogammaglobulinemia,
requiring replacement therapy; reduced CD19+ B cells;
invertedCD4+/CD8+ ratio; reducedCD4+, CD8+, and recent
thymic emigrants; and reduced regulatory T cells. The studies
on the neutrophils revealed impaired chemiotaxis, reduced
number of neutrophil granules, and morphological changes
of the secondary granules. However, neutrophil dysfunction
in these patients was not associated with the development
of severe clinical manifestations in the neonatal period. The
impairment of the B and T cell compartments observed in
these patients supports the role of RAC2 in the B and T cell
development, also observed in mouse models [110–113].
4. Chronic Granulomatous Disease:
Clinical Manifestations
CGD is characterized by an increased susceptibility to recur-
rent or severe infections due to fungal or bacterial pathogens.
Infections are typically caused by catalase-positive bacteria
and fungi. The most common microorganisms are Aspergil-
lus species, Staphylococcus aureus (S. aureus), Burkholderia
(Pseudomonas) cepacia complex (B. cepacia), Serratia mar-
cescens (S. marcescens), and Nocardia species [14]. Salmo-
nella and Bacillus Calmette-Guérin (BCG) are common
pathogens in patients coming from countries with high prev-
alence of Salmonella, with endemic tuberculosis and manda-
tory BCG vaccine (Table 1). Other rare bacterial species have
been recognized in patients with CGD, and the identiﬁcation
of these pathogens is virtually pathognomonic of the disease
(Table 1). Among those, it is important to mention sepsis by
brackish water organisms Chromobacterium violaceum [114]
and Francisella philomiragia [115]. Another emerging cause
of necrotizing lymphadenitis and sepsis are methylotrophs
like [116] Granulibacter bethesdensis [117, 118], Acidomonas
methanolica [119], and Methylobacterium lusitanum [120].
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PCR for 16S rRNA is necessary for the identiﬁcation of the
atypical pathogens [116]. Chronic recurrent pulmonary,
hepatic, and cervicofacial infections by catalase-negative acti-
nomycosis have also been reported [121]. Table 1 summarizes
the most common and the pathogenetic microorganisms
isolated in patients with CGD.
Median age at diagnosis ranges from 2.5 to 3 years. Two
thirds of the patients are diagnosed in the ﬁrst year of life and
usually before 5 years of age. The X-linked variants display a
more severe clinical picture, accounting for most of the early
presentations. On the other hand, AR variants can display
milder phenotypes and delayed diagnosis [122–128]. The
most common sites of infections are the lungs, lymph nodes,
skin, and liver, even though also the bones, kidneys, gastroin-
testinal tract, and brain may be aﬀected. Presenting features
may also include diarrhea, failure to thrive, delayed wound
healing, and granuloma formation in multiple organs. Clini-
cal manifestations may be very diﬀerent among patients.
4.1. Lung Involvement in CGD. Pulmonary infections are the
most common manifestations among all the disease variants.
Radiologic ﬁndings include consolidation, nodules, areas of
scarring, traction bronchiectasis, emphysema, air trapping,
mediastinal and hilar lymphadenopathy, pulmonary artery
enlargement, and pleural eﬀusion [129]. Pneumonias are
recurrent and resistant to standard therapy and can often
complicate with granulomatous hilar lymphadenopathy,
mimicking sarcoidosis, lung abscesses, and empyema. S.
aureus was the most common pathogen in lung infections
previous to the use of trimethoprim/sulfamethoxazole pro-
phylaxis. In the postprophylaxis era, other bacteria and fungi
are the more common causes of pneumonia. B. cepacia
complex may lead to severe lung infections, bearing a signif-
icant morbidity due to the resistance to ﬁrst-line empiric
antibiotic treatments and the delayed diagnosis related to
the diﬃculties in its isolation and growth [130]. Lung infec-
tions by Nocardia often require invasive techniques for the
isolation and the deﬁnition of speciﬁc antibiotic therapies.
In one third of the cases, Aspergillus infections are identiﬁed
along with Nocardia infections, probably because both of
them are acquired through inhalation [131]. Interestingly,
diﬀerently from fungal infections, Nocardia is able to cause
lung cavitations in patients with CGD. In countries with
endemic tuberculosis or mandatory BCG vaccine, localized
or widespread mycobacteria infections are very common,
leading to the diagnosis in most of the cases. In a recent sur-
vey, mycobacterial infections were identiﬁed as responsible
for 6% of pneumonias in American patients with CGD
[124]. Infections by environmental mycobacteria like M.
leprae orM. ulcerans are uncommon. BCG vaccine is contra-
indicated in patients with CGD [132, 133]. Fungal infections
due to inhalation of spores and hyphae are an important
cause of morbidity in patients with CGD, and they lead to
diagnosis in most of the cases. They may present with insid-
ious and subclinical courses, with aspeciﬁc symptoms like
growth failure and asthenia, low-grade fever, cough or chest
pain, and mild leukocytosis. On the other hand, the inhala-
tion of aerosolized decayed organic matter, including fungi,
can cause an acute fulminant pneumonitis also known as
“mulch pneumonitis” [134]. Lung infections are typically
caused by Aspergillus species (Figure 2(a)), and A. fumigatus
is the most common [135]. Other variants like A. nidulans
[136], A. viridinutans, and Neosartorya udagawae [137] are
almost pathognomonic for CGD and can cause invasive
spreading disease to the bones and nervous system [138].
Other fungal pathogens isolated in patients with CGD
include molds Paecilomyces lilacinus [139] and variotii
[140], Geosmithia argillacea [141–143], the fungus Penicil-
lium piceum [144], and the basidiomycetes of the Phellinus
species [145]. The recognition of atypical fungal infections
can be challenging due to the need for nonstandard culture
conditions. For this reason, extensive and aggressive diag-
nostic approaches, including molecular diagnostic, should
be always undertaken in order to identify the pathogens,
especially when the patient is under mold prophylaxis
[138, 146]. Yeast infections are less common in patients
with CGD. Mucormycosis has been only reported in the set-
ting of immunosuppression [137], and dimorphic mold
infections like Coccidioidomycosis and Blastomycosis are
not typical [147].
4.2. The Skin and Lymph Nodes. Cutaneous involvement with
abscesses and deep seeded infections is also common. The
pathogens implicated are typically S. aureus, catalase-
positive and gram-negative bacteria. Cutaneous abscesses
may often require prolonged antibiotic courses, incision,
and drainage procedures for resolution. Impetigo in the nasal
area and resistant facial acne caused by S. aureus also require
long courses of local and systemic antibiotics [148–154]. Sup-
purative adenitis due to S. aureus has been reported. Granu-
libacter bethesdensis is an environmental organism that can
Table 1: Microorganisms causing infections in CGD
Common Reference
Aspergillus species
[14]
Staphylococcus aureus
Burkholderia cepacia complex
Serratia marcescens
Nocardia
Salmonella
Bacillus Calmette-Guérin (BCG)
Pathognomonic
Chromobacterium violaceum [114]
Francisella philomiragia [115]
Granulibacter bethesdensis, [117, 118]
Acidomonas methanolica [119]
Methylobacterium lusitanum [120]
Actinomycosis [121]
A. nidulans and viridinutans [136]
Neosartorya udagawae [137]
Paecilomyces lilacinus and variotii [139, 140]
Geosmithia argillacea [141–143]
Penicillium piceum [144]
Phellinus species [145]
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lead to necrotizing pyogranulomatous lymphadenitis and in
rare cases fatal bacteremia. Noninfectious manifestations of
CGD include photosensitivity, discoid lupus, granuloma-
tous lesions, and vasculitis. Patients with CGD display typ-
ically delayed and abnormal wound healing caused by
excessive granulation, causing scarring and wound dehis-
cence [151].
4.3. The Liver. Hepatic and perihepatic abscesses are com-
mon in CGD. Liver involvement may lead to morbidity due
to the challenging diagnosis and treatment. Presentation
can be subtle, with aspeciﬁc systemic symptoms. Diﬀerently
from hepatic abscesses in immunocompetent patients, com-
monly caused by enteric bacteria, abscesses in CGD are
mainly caused by staphylococci. These abscesses are usually
very dense and may require diﬃcult surgical procedures in
most of the cases. Recently, the association of high-dose ste-
roids and antibiotic regimens has been proved to be an eﬀec-
tive surgical sparing approach [155, 156]. Noninfectious
causes of liver involvement in patients with CGD include
toxic drug-induced hepatitis, hepatosplenomegaly due to
portal venopathy, and nodular regenerative hyperplasia.
The development of noncirrhotic portal hypertension is a
negative prognostic factor [157, 158].
4.4. Metastatic Infections. Osteomyelitis is one of the most
important metastatic infections in patients with CGD. It is
characteristically multifocal, with other organs involved,
caused by typical CGD pathogens like S. marcescens orAsper-
gillus species. Biopsy reveals signs of chronic inﬂammation
and granulomatous features [159, 160]. Infection spreading
can also aﬀect the central nervous system, presenting with
meningitis, brain, and epidural abscesses (Figures 2(b)–2(e))
[148–150]. Genitourinary tract involvement is also frequent
(38%), but often occult. Granulomatous cystitis, ureteral
and urethral obstruction, prostate abscesses, bladder granu-
lomata, and urinary tract infections have been reported
[161–164]. Chorioretinal lesions are relatively common in
patients with CGD, typically with “punched out” lesions
associated with pigment clumping lying in line with the reti-
nal arteries. Those lesions appear to be nonprogressive and
usually do not impair vision [165]. Since bacterial DNA
was isolated from those lesions, infections may play a role
in the pathogenesis [166]. However, these lesions in most
cases do not progress during immunosuppression suggesting
that they are not sites of active infections [122]. Patients can
also present with blepharokeratoconjunctivitis and pannus
formation [167].
4.5. The Gastrointestinal Tract. The gastrointestinal tract is
extensively aﬀected in patients with CGD. Granulomatous
disease-mimicking Crohn’s disease, aﬀecting the oesophagus,
stomach, jejunum, ileum, cecum, and rectum, is common [8,
152–154, 168]. Also, the upper gastrointestinal tract may be
involved in the forms of gingivitis and gingival hypertrophy,
stomatitis, and aphthosis. Around a third of patients are
aﬀected, being more frequent in the X-linked forms (43%)
then in the autosomal recessive (11%). In some cases, it
may represent the only manifestation of the disease. In such
cases, diagnosis may be challenging [169]. Clinical presenta-
tion is variable, ranging from gastric outlet obstruction [170],
malabsorption, vitamin B12 deﬁciency to classic inﬂamma-
tory bowel disease symptoms like abdominal pain, diarrhea,
ﬁstulae, and strictures. CGD-related colitis is often resistant
to the standard inﬂammatory bowel disease therapies. The
treatment with anti-TNF-α drugs has been successfully used
to treat ﬁstulas, but it may increase the risk of severe infec-
tions [171].
4.6. Brain Disease. The assessment of cognitive function in 23
patients with CGD revealed an increased prevalence of cog-
nitive deﬁcit (IQ< 70%) [172]. However, this evidence was
not conﬁrmed in a subsequent study [173]. It should be noted
that in both the studies, the sample size was quite small to
draw deﬁnitive conclusions. Considering the role of superox-
ide generation in brain hippocampal synaptic plasticity and
hippocampus-dependent memory, this subject deserves
further studies [174]. On the other hand, increased levels of
NOX2 have been detected in microglia and inﬁltrating
macrophages in brain autopsies from patients with initial
multiple sclerosis, suggesting a role of ROS in the pathogen-
esis of demyelination and neurodegeneration [175]. This
(b)
(c) (d)
(e)(a)
Figure 2: Invasive fungal infections in patients with CGD. (a, b) Cerebral invasion (arrows) in a patient with invasive pulmonary aspergillosis.
(c) Cerebellar aspergillosis (arrow). (d) Invasive pulmonary aspergillosis. (e) Spinal cord invasion (arrow) in a patient with pulmonary
aspergillosis.
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hypothesis has been conﬁrmed by the evidence of the
involvement of NOX2 in motor neuron degeneration in a
mouse model of amyotrophic lateral sclerosis [176].
4.7. Growth Defect. Children with CGD usually attain a
height within their target by adulthood, despite being gener-
ally small for their age in early childhood. Growth failure
might be linked to colitis and malabsorption and to the
chronic and frequent infections [177]. Regardless of the
cause, hematopoietic cell transplantation is able to reverse
most of the cases of growth defect [178].
4.8. Laboratory Findings. Patients with CGD may show a
mild to moderate leukocytosis, elevation of acute phase reac-
tants, and polyclonal hypergammaglobulinemia. A chronic
microcytic anemia due to chronic disease and iron deﬁciency
may be observed at the onset of the disease, especially in asso-
ciation with colitis. Patients can also display a T CD4+ lym-
phopenia [179, 180].
4.9. McLeod Phenotype. The CYBB gene, responsible of the X-
linked CGD variant, is located at the Xp21.1 locus. Deletions
across this locus can also involve adjacent genes, generating
complex phenotypes. Telomerically to theX-CGD locus, there
are the Kell erythrocyte antigens. Their deletion causes the
McLeod phenotype, a syndrome with haemolytic anemia
associated with neuroacanthocytosis [181, 182]. For this rea-
son, patients with X-linked CGD need to be carefully evalu-
ated for their Kell phenotype in order to avoid sensitization
and transfusion reactions [183]. Larger telomeric deletions
can also involve the retinitis pigmentosa GTPase regulator
(RPGR) gene, responsible for X-linked retinitis pigmentosa,
and DMD, causing Duchenne muscular dystrophy. Large
centromeric deletions can involve the OTC gene, causing
ornithine transcarbamylase deﬁciency [184].
5. Williams Syndrome
Williams syndrome (WS) is a rare genetic disorder, aﬀecting
1/20000 newborns, characterized by neurodevelopmental
alterations leading to mild-to-moderate mental retardation
and characteristic craniofacial features. Supravalvular aortic
stenosis and hypercalcemia in infancy may also feature the
disease. WS is due to a heterozygous segmental microdele-
tion (about 1.5–1.8Mb) at chromosomal band 7q11.23.
This deletion involves about 20 genes and, in some cases,
it may also include the NCF1 gene. In extremely rare cases,
the WS microdeletion may be associated with a mutation in
NCF1 on the other allele. When the WS deletion includes
NCF1, this combination leads to the development of CGD
[185, 186].
6. NADPH Oxidase Deficiency and
Autoimmunity: A Focus on Female Carriers
and Patients Carrying Oxidase
Gene Polymorphisms
Autoinﬂammatory and autoimmune disorders have been
identiﬁed in patients with CGD, female carriers for NOX2
deﬁciency, and patients carrying oxidase gene polymorphisms,
suggesting a role for NADPH oxidase in the pathogenesis of
autoimmunity and in the in regulation of the adaptive
immune responses [187–189]. In a recent study, Wen et al.
showed that NOX2 is critical for the correct functioning of
the suppressive machinery of CD8+ T regulatory cells (CD8
Treg) [190]. In particular, CD8 Treg are able to control the
intensity of eﬀector T cell responses by releasing NOX2-
containing microvesicles which are in turn taken up by the
target cells [190]. NOX2-derived ROS abrogate the phos-
phorylation of ZAP70 and LAT preventing the activation
of the eﬀector cell [190]. This mechanism is impaired in
older individuals and is related to the development of auto-
immunity [190]. Finally, NOX2 overexpression is able to
restore the suppressive function of CD8 Tregs from older
donors [190].
Genome-wide association studies (GWAS) have revealed
the association between genes-encoding oxidase subunits
and autoinﬂammatory and autoimmune disorders. The most
common autoimmune manifestations in CGD are systemic
lupus erythematosus (SLE) [124–126, 191, 192], followed by
thrombocytopenic purpura (ITP) [124–126, 191, 193–195]
and arthritis [125, 192, 193, 196]. Variations inNCF2, encod-
ing p67phox, and NCF4, encoding p40phox, have been asso-
ciated with SLE [197] and with rheumatoid arthritis [198]
and Crohn’s disease [199, 200], respectively. Moreover, a
recent study revealed that p47phox-deﬁcient patients are
at greater risk of developing severe diabetes and the related
complications, including renal and cardiovascular disease,
as compared with patients with NOX2 deﬁciency [201].
Similarly, GWAS studies revealed variants in NOX2 com-
plex components in patients suﬀering from very early onset
inﬂammatory bowel disease (VEOIBD) [202–204]. Apart
from NOX2, also other NOX homologues seem to play a
role in the development of VEOIBD. In a recent study,
two variants of NOX1 have been identiﬁed in three patients
with severe pancolitis [205]. The ﬁrst patient carried a mis-
sense variant located upstream of the ﬁrst FAD-binding
domain. This mutation lead to a reduction of ROS genera-
tion by 50–60% [205]. The second variant was located in
the second FAD-binding domain and led to a 60–80%
decrease in ROS production. Similarly, a DUOX2 missense
variant was identiﬁed in a patient with recurrent pancolitis,
complicated by perforation and colectomy. The variant was
located in the third intracellular loop and leads to reduced
H2O2 generation [205]. A second DUOX variant located
in the highly conserved GRP sequence in the third
NADPH-binding domain was identiﬁed in a patient with
pancolitis [205]. This variant also led to decrease in H2O2
release [205].
Female carriers for NOX2 deﬁciency are not completely
asymptomatic. In aﬀected women, lyonization determines
two populations of phagocytes. One with normal oxidative
activity and another with impaired oxidative activity. Usu-
ally, 15 to 20 percent of wild-type cells are suﬃcient to handle
infections. However, in case of unbalanced lyonization lead-
ing to less than 20 percent of normal oxidase activity, female
subjects can show mild to severe CGD phenotype (Figure 3).
Skewing of X-chromosome inactivation can be progressive
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with aging leading to late onset CGD manifestations and
increased rate of autoimmunity including inﬂammatory
bowel disease [206–209]. The most common ﬁndings in het-
erozygous female carriers are photosensitive skin rashes
(58%), mouth ulcers (42%), and joint pain (37%). The cuta-
neous rash closely resembles chronic discoid lupus, even
though systemic lupus serologic markers are usually negative
(Figure 3) [210–212]. Asymptomatic carriers can also have
the typical chorioretinal lesions. All the abovementioned
manifestations seem to be associated with skewed lyonization
[165, 167]. In a few cases, a severe phenotype, requiring
HSCT, has been described in X-CGD female with nonran-
dom X-chromosome inactivation [213].
Both the X-CGD carrier status and X-chromosome inac-
tivation can be identiﬁed with the dihydrorhodamine (DHR)
123 testing. Recently, Marciano et al. studied a large cohort of
X-linked CGD female comparing the presence of infections
and/or autoinﬂammatory manifestations with the levels of
DHR in the peripheral blood neutrophil. Overall, 48% of X-
CGD carrier had a clinical history of infections and/or auto-
immune or inﬂammatory manifestations. A signiﬁcant cor-
relation was found between the development of infections
and levels of DHR lower than 20%. Furthermore, the authors
found that carriers more prone to develop severe infections
had DHR lower than 10%. No correlation was found between
diﬀerent NOX2 mutations and % of DHR values. However,
diﬀerently from what was observed for the infections, it was
not possible to ﬁnd any relationship between the DHR levels
and the incidence of autoimmune or inﬂammatory manifes-
tations. These data support the hypothesis that, diﬀerently
from infectious complications, the development of inﬂam-
matory manifestations is not correlated with the residual
reactive oxygen intermediate production but to the carrier
status per se. Further factors, including the inﬂuence of con-
founder genes, and environmental factors such as the
microbiome may contribute to the development of these
manifestations [191, 214]. Considering that the X inactiva-
tion can be diﬀerent between tissues, further studies are
necessary to deﬁne the role of X inactivation in the patho-
genesis of inﬂammatory or autoimmune manifestations in
X-CGD carriers.
7. NADPH-Dependent ROS Deficiency and
Autophagic Dysfunction: Implication for
Infectious Response and Inflammasome
Activation
Autophagy is implicated in many tissue-speciﬁc functions
and cellular pathways, including those involved in both
innate and adaptive immunity [215, 216]. Autophagy is a
fundamental metabolic pathway implicated in delivering
cytoplasmic proteins and organelles to the lysosome for deg-
radation. Recent evidence suggests that autophagy is also
implicated in innate immune response pathways and in par-
ticular in targeting intracellular bacteria in the cytosol and in
limiting bacterial growth in damaged vacuoles and phago-
somes. The process, also known as “xenophagy,” involves
the formation of double-membrane compartments, namely,
autophagosomes, around target bacteria and their transport
to lysosomes, where they are degraded [217, 218]. In particu-
lar, this mechanism seems to be mainly implicated in the
defence against intracellular infectious agents, including
Mycobacterium tuberculosis, Salmonella, Shigella, Legionella,
Burkholderia species, and Aspergillus fumigatus [219–221].
Most of these infectious agents are usually responsible for
fatal or severe infections in patients aﬀected with CGD. On
the other hand, bacteria have developed several mechanisms
to impair autophagy interfering with autophagy signalling or
the autophagy machinery [222]. The evidence that the LC3
(light chain 3) protein, a member of the autophagy-related
family (Atg) and beclin 1, another autophagic component,
is able, upon bacterial cellular engulfment, to bind to the pha-
gosomes promoting their fusion with lysosomes and the kill-
ing of the enclosed microbes suggested that autophagy may
be implicated in antimicrobial defence [223]. This process
has been found strongly decreased in phagocytes from
Nox2 KO mice [224]. Furthermore, it has been observed that
in both human and murine models of CGD macrophages,
which explain a permissive phenotype for bacterial replica-
tion, autophagy induction by rapamycin, a mammalian tar-
get of rapamycin (mTOR) inhibitor, is able to reduce B.
cenocepacia bacterial burden, suggesting that the increase of
CGD patients Carriers Hyperfunction
DHR<10%
Infections
Impaired inflammatory response
Autoimmunity
Autoimmunity
Neurodegenerative diseases
Neoplasms
Cardiovascular diseases
Figure 3: Spectrum of clinical manifestations associated with marked reduction (dihydrorhodamine (DHR)< 10%), slight reduction, and
increase of the NOX2 activity. The complete absence of NOX2 activity leads to the development of infectious, inﬂammatory and
autoimmune complications observed in CGD. A partial reduction of the NOX2 activity, observed in female carriers, may lead to the
development of autoimmune complications. Upregulation of NOX2 has been observed in diﬀerent cardiovascular and neurodegenerative
disorders and in neoplasms.
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the autophagic ﬂux may represent a potential therapeutic
approach to improve bacterial clearance in CGD [219]. A
normal ROS production is considered indispensable for the
physiological activation of the autophagic process [225]. On
the other hand, the integrity of the autophagic machinery
results in the inhibition of IL-1β production. In a recent
study, ROS deﬁciency has been associated with defects of
autophagic mechanism in both mice and patients with
CGD. In this study, the human subunit p47phox was showed
to be fundamental for LC3 recruitment after the bacterial
internalization. Moreover, it was observed that IL-1β pro-
duction from human CGD monocytes was signiﬁcantly
increased as compared to normal controls. The blocking of
the IL-1 receptor with anakinra resulted in a signiﬁcant
reduction of the inﬂammation in p47phox−/− mice aﬀected
with colitis associated with a reduced production of inﬂam-
matory cytokine. A clinical improvement of the colitis and
perirectal abscesses was, also, observed in two CGD patients
aﬀected with active colitis, treated with the same drug [15].
Unfortunately, anakinra did not induce a clinical remission
in further ﬁve cases [14]. According to the indication of the
European Medicines Agency, the dose of anakinra may be
gradually increased to a maximum of 8mg/kg/day, based
on the individual therapeutic response (http://www.ema.
europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/000363/WC500042310.pdf). Since in the
study by Hahn et al. the protocol of treatment and exact dose
of drug used per patient are not speciﬁed, it is not possible to
rule out that the dose of drug used was too low. The treat-
ment with anakinra was shown to be able to modulate the
increased inﬂammasome activation and to restore the abnor-
mal autophagy in both human and mouse cells. In CGDmice
infected with Aspergillus fumigatus, the treatment with ana-
kinra was also associated with a reduction of fungal growth
and granuloma formation resulting in an increased survival.
This last evidence suggests that the pharmacological restora-
tion of the autophagy may be also useful in treating severe
fungal infection. In a further study by Gabrion et al. [17],
rapamycin was able to induce a reversion of CGD inﬂamma-
tory status in diﬀerent immune cells of patients with CGD. In
particular, rapamycin was able to induce a reduction of the
production of IL-1β, IL-6, IL-23, and TNF-alpha in macro-
phage stimulated with LPS, a reduction of the IL-6/IL-10 pro-
inﬂammatory ratio, and a decrease of the inﬂammasome
activation. Moreover, the addition of low doses of anakinra
was able to potentiate the inhibitory eﬀect of rapamycin on
IL-1β secretion in vitro. Therefore, drugs that modulate
autophagy may represent a potential therapy for both infec-
tious and inﬂammatory manifestations associated to this
complex congenital disorder.
8. NADPH Oxidase Upregulation and
Vascular Disease
Apart from the phagocytes, where it has been originally
identiﬁed, NOX2 is also expressed in endothelial cells [18],
cardiomyocytes [19], hematopoietic stem cells [20, 21], and
platelets [22]. NOX2 upregulation has been shown to be
involved in neurodegenerative diseases [23], neoplasms
[24], and cardiovascular diseases [25–28]. NOX can exert
damaging as well as protective roles in the vascular system.
In fact, while a regulated production of H2O2 is necessary
to maintain the integrity of the endothelial system and to
control the inﬂammatory response [226], on the other hand,
the hyperproduction of H2O2 may lead to inﬂammation, oxi-
dative stress, and endothelial disfunction [227–229]. Among
the diﬀerent vascular NADPH oxidase isoforms, NOX2 is the
most widely expressed and it has been identiﬁed in VSMCs,
adventitial ﬁbroblasts, endothelial cells, and perivascular adi-
pocytes [18, 230, 231]. In the cells of the vascular system, the
structure of NOX2 complex is similar to that found in phago-
cytes. However, in some conditions, NOX organizer protein
1 (NOXO1) and NOX activator protein 1 (NOXA1) may play
a role in the activation of NOX2 complex [232]. NOX2 is
implicated in proliferation and vascular endothelial growth
factor- (VEGF-) induced migration [233] and in the regula-
tion of the expression of adhesion molecules during inﬂam-
mation and angiogenesis.
Recent studies suggest that NOX2 activation is involved
in atherosclerosis [234–236]. Several experimental studies
showed an upregulation of the NOX2 in the atheroma from
carotid [237–239] and coronary sites [240, 241]. In an exper-
imental model of carotid lesion induced by ﬂow cessation,
the overexpression of the NOX subunit p22phox led to a pro-
gression of carotid artery lesions, which was more marked
compared to lesions in wild-type mice [242]. In atheroscle-
rotic coronary arteries, p22phox was overexpressed in the
neointimal and medial smooth cells and in inﬁltrating
macrophages in hypercellular regions at the border of ather-
omatous plaques [243]. Furthermore, enhanced superoxide
production was detected in coronary arteries from patients
with coronary heart disease in association with upregulation
of p22phox and NOX2 suggesting that both these subunits
contribute to oxidative stress in human coronary atheroscle-
rotic lesions [244]. Endothelial cells produce O2
− prevalently
via diﬀerent NOX isoforms such as NOX1, NOX2, NOX4,
and NOX5, which may contribute to modulate arterial dilata-
tion with diﬀerent mechanisms [245, 246]. Flow-mediated
dilatation (FMD), which is dependent upon endothelial
release of NO and is considered a surrogate marker of athero-
sclerosis [29], has been evaluated in patients with NOX2 (X-
linked CGD) [30] or p47phox hereditary deﬁciency. Patients
with NOX2 and p47phox hereditary deﬁciency showed
enhanced FMD, which, however, was more marked in
NOX2-deﬁcient patients suggesting a relationship between
rate of ROS formation and artery vasoconstriction [30–32].
In accordance with these studies, compared to controls,
higher values of FMD were found in carriers of hereditary
deﬁciency of NOX2, suggesting that also a partial reduction
of NOX2 can contribute to increase endothelial function
[247]. The mechanism accounting for enhanced artery dila-
tation was attributed to heightened NO generation, which
was also suggested to account for enhanced vasodilation
detected in animal knockout for NOX2 [248, 249]. The evi-
dence that the intravenous injection of L-NAME, an inhibi-
tor of NO synthase, is able to blunt the increase of the
FMD in patients with X-linked CGD [32] also conﬁrms this
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hypothesis. The close relationship between endothelial dys-
function and NOX2 has been also studied in other models
including dyslipidemia, obesity, smoking [250, 251], hyper-
tension, metabolic syndrome, diabetes mellitus, peripheral
arterial disease [252], and obstructive sleep apnea [253].
These classic cardiovascular risk factors provoke endothelial
dysfunction even in childhood, and the coexistence of
NOX2 regulation suggests this enzyme as a potential trigger
[254–256]. In fact, children with hypercholesterolemia, obe-
sity, or obstructive sleep apnea displayed NOX2 upregulation
coincidentally with a reduced FMD [30, 254–256]. A signiﬁ-
cant reduction of carotid intima-media thickness (IMT) [30],
which is a surrogate marker of atherosclerosis, has been
detected by Doppler ultrasonography [257] in children [30]
with CGD and later conﬁrmed in an adult cohort of female
carriers with NOX2 deﬁciency [247]. The same evidence
was then conﬁrmed using a more sophisticated diagnostic
approach, that is, magnetic resonance imaging and com-
puted tomography, which showed that CGD patients, com-
pared with control subjects, had a 22% lower internal
carotid artery wall volume with a similar reduction detected
in both the p47phox- and NOX2-deﬁcient subtypes [258].
Based on the above-reported experimental and clinical data,
NOX2 could be suggested as potential target to counteract
the process of atherothrombosis; however, interventional
studies with NOX2 inhibitors are warranted to assess the
clinical validity of this therapeutic approach in patients at
risk or with cardiovascular events. Apart from NOX2, also
NOX4, NOX5, p22phox, and, to a lesser extent, NOX1 may
be implicated in the pathogenesis of atherosclerosis [234,
259]. In particular, similarly to NOX2, NOX1 seems to be
implicated in the acute response to injury or to angiotensin
II stimulation. On the contrary, NOX4 seems to be able
to maintain VSMC in a quiescent status [237]. For this
reason, the association of high levels of NOX2 and low
levels of NOX4 may lead to the development of intimal
hyperplasia, remodelling, and accelerated atherosclerosis
in vein grafts [260]. NOX5 is also overexpressed in coro-
nary artery obtained from patients with coronary artery
disease [261]. The increase of NADPH oxidase activity
may also contribute to the development of atherosclerosis
through lipid oxidation.
NADPH oxidase is also implicated in the pathogenesis of
hypertension. Angiotensin II, which plays a critical role in
the pathogenesis of hypertension, is able to induce the
expression of diﬀerent NOX homologues, including NOX1,
NOX2, NOX4, and p22phox [26, 233, 262]. The induction
of the NOX by angiotensin II increases the production of
superoxide and H2O2 in VSMC, also leading to vascular
hypertrophy. In a mouse model of p47phox deﬁciency,
angiotensin II was not able to induce an increase of the pro-
duction of O2
−, diﬀerent from what was observed in wild-
type mouse [263] suggesting that p47phox deﬁciency is able
to attenuate angiotensin II-induced hypertension [264] and
endothelial dysfunction [265]. Deletion of p47phox was also
associated with the prevention of angiotensin II-induced
aneurysm formation [266–268] and myocardial infarction-
induced cardiac dysfunction [263]. p47phox deﬁciency is able
to impair both NOX1 and NOX2 activation. Overexpression
in VSMC ofNOX1 and p22phox inmouse has been associated
with elevation of blood pressure in response to angiotensin
II and with the development of vascular hypertrophy
[269–271]. On the other hand, the deletion of both the sub-
unit has a protective role against the development of endo-
thelial dysfunction, oxidative stress, vascular hypertrophy,
and aortic dissection [248, 272–274]. NOX2 is implicated
in the development of vascular hypertrophy [275] and
endothelial dysfunction [276], but it does not seem to be
directly implicated in the regulation of blood pressure
[275]. NOX4 overexpression in endothelial cells is associated
with vasodilatation and reduced blood pressure, suggesting
that it has a protective role in hypertension and the related
complications [277]. Evidence suggest that NOX4 may have
a protective role in ischemic and hypertensive stress [278].
However, studies in the brain suggest that NOX4 contrib-
utes to the oxidative stress in the context of stoke or other
pathologic conditions [279].
NOX1 and NOX4 are also implicated in the pathogenesis
of long-term macrovascular complications in diabetic
patients [280]. Hyperglycaemia is able to directly induce the
NADPH oxidase leading to increased ROS production and
eventually to endothelial dysfunction [281].
Vascular NADPH oxidase also plays an important role in
tumour growth [282] and ischemic revascularization [283].
In particular, NOX2 is implicated in endothelial cell migra-
tion [283] and NOX1, NOX4, and NOX5 are implicated in
angiogenesis and neovascularization [284]. NADPH oxidase
may be activated by diﬀerent proangiogenic factors [285],
including VEGF [286], and in turn can modulate the release
of diﬀerent angiogenesis-related factors, including VEGF-A
[287], hypoxia-induced factor 1a (HIF-1a) [288], and matrix
metalloproteinases (MMPs) [289, 290].
In pulmonary artery smooth muscle cells (PASMCs),
NOX2 and NOX4 are involved in the development of pulmo-
nary hypertension in response to chronic hypoxia [291, 292].
In particular, in response to hypoxia, the ROS produced by
NOX2 activate NOX4 which in turn is able to bind HIF-1α,
leading to PASMC proliferation [285, 292].
Finally, NOX1, NOX2, and NOX5 are also implicated
in the regulation of the expression of the endothelial adhe-
sion molecules, including vascular cell adhesion molecule 1
(VCAM-1), intercellular adhesion molecule 1 (ICAM-1),
and P- and E-selectins. The increased expression of these
molecules leads to transmigration of leukocytes into the
subendothelial space [293] which is implicated in early
atherosclerosis [294–296] or hypertensive vascular dys-
function [297].
9. Hematopoietic Stem Cell
Transplantation for the Treatment of CGD
To date, hematopoietic stem cell transplantation (HSCT)
represents the only available potentially curative treatment
for patients with CGD of any genetic origin. In the last
decade, improvements in HSCT protocols led to a signiﬁcant
improvement of the survival of patients with X-linked CGD
(Figure 4). Currently, the two most common conditioning
regimens include reduced intensity conditioning (RIC),
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typically busulfan based or a reduced toxicity regimen
(typically treosulfan based). Both of them have resulted in
an extremely improved survival (>90%) [298–301]. These
encouraging results corroborate the priority to extend the
HSCT indications. In 2014, Güngör et al. published the larg-
est prospective study of a reduced intensity conditioning reg-
imen for HSCT in pediatric and adult patients with CGD
[300]. In this study, HSCT was only considered in patients
with more than one life-threatening infection, no compliance
with antimicrobial prophylaxis, or steroid-dependent autoin-
ﬂammation [300]. However, other studies showed an impres-
sive lower survival rate in patients with X-linked CGD
treated conventionally with antibiotic and antifungal pro-
phylaxis as compared with patients treated with HSCT
[302]. In fact, patients surviving childhood face a high
mortality due to a cumulative organ injury that could also
dramatically aﬀect HSCT outcome or even preclude this
treatment [303]. For this reason, current clinical manage-
ment of these fragile patients suggests that HSCT should be
considered as a reasonable curative treatment for a wider
group of patients as soon as possible and, when possible,
before the onset of severe complications [302]. Apart from
preexisting comorbidities and organ dysfunction, standard
myeloablative conditioning protocols were also responsible
for the striking transplant-related mortality observed in the
past. Granulocyte infusions and more recently the use of
pioglitazone, that can bypass the inability of NADPH oxidase
complex by increasing mitochondrial reactive oxygen spe-
cies, suggest relevant insights in the treatment of this rare
disease [304, 305].
10. Gene Therapy for the Treatment of
X-Linked CGD
The evidence of the high success rate of earlyHSCT in patients
with CGD [201, 300, 306, 307] has opened the way to gene
therapy (GT) approach for patients without amatched donor.
A protocol based on γ retrovirus (γRV) GT without condi-
tioning was developed and resulted in transitory functional
correction of ≤0.5% of peripheral blood granulocytes, with-
out any long-term clinical beneﬁt [308, 309]. The main rea-
sons of the failure of this approach were the lack of survival
advantage of the transduced neutrophils over the defective
ones, their short lifespan, and the inﬂammatory bone mar-
row milieu, with a potential negative eﬀect on HSC gene
transfer [310–312]. Subsequent trials with γRV vector-trans-
duced, mobilized CD34+ cells were attempted between 2000
and 2010 [306, 311, 313, 314]. However, in most of the cases,
a loss of the long-term engraftment of transduced cells [315]
was observed. Moreover, this approach was also complicated
by the occurrence of myelodysplasia and clonal expansion
in both adult and pediatric patients. The safety concern
led to the clinical use of regulated SIN-lentiviral vectors tar-
geting NOX2 expression in myeloid cells. In vitro and
in vivo murine studies showed that this vector is able to
restore NADPH oxidase activity and has a safer proﬁle
[316]. This vector is currently employed in multicenter trials
in Europe and in the USA (NCT01906541, NCT01855685,
and NCT02234934).
11. Conclusions and Perspective
Loss-of-function mutations in genes encoding for various
NADPH oxidase subunits lead to a phenotype mainly char-
acterized by severe and recurrent infections. However, recent
evidence shows that NADPH oxidase is also implicated in the
regulation of several diverse mechanisms. The aim of this
review is to focus on the most recent evidence regarding the
biological role of NADPH oxidase and its implication in the
typical CGD clinical manifestations, as well as in the more
recently deﬁned clinical features, including autoinﬂamma-
tory manifestations. The identiﬁcation of the pathogenic
mechanisms underlying inﬂammatory complications has
led to the identiﬁcation of novel potential curative and symp-
tomatic approaches, whose eﬀectiveness in vitro and in vivo
has been explored in some preliminary models and clinical
trials. New biological roles of NADPH oxidase are emerging,
that is, the implication in the pathogenesis of atherosclerosis.
(a) (b)
Figure 4: CT scan of a possible invasive fungal infection in a 5-month-old XCGD patient (a) pre-HSCT and (b) after HSCT. A progressive
improvement of the areas of consolidation in the left and right lungs, especially for the right lobes, is observed. Residual pulmonary lesions are
visible in the left and right inferior lobe.
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These observations are paving the way for future observa-
tional and interventional studies on CGD-aﬀected patients
and carriers.
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